Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
4.080
+0.520 (14.61%)
At close: Aug 29, 2025, 4:00 PM
4.059
-0.021 (-0.52%)
After-hours: Aug 29, 2025, 6:48 PM EDT
Company Description
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases.
Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024.
The company was incorporated in 2019 and is based in Palo Alto, California.
Kalaris Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Andrew Oxtoby |
Contact Details
Address: 628 Middlefield Road Palo Alto, California 94301 United States | |
| Website | kalaristx.com |
Stock Details
| Ticker Symbol | KLRS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001754068 |
| CUSIP Number | 482929106 |
| ISIN Number | US4829291065 |
| Employer ID | 83-1971007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Andrew Oxtoby | President, Chief Executive Officer and Director |
| Dr. Srinivas Akkaraju M.D., Ph.D. | Director and Co-Founder |
| Dr. Michael Philip Dybbs Ph.D. | Director and Co-Founder |
| Dr. Napoleone Ferrara M.D. | Independent Director and Co-Founder |
| Brett R. Hagen | Senior Vice President Finance, CAO and Principal Financial Officer |
| Dr. Matthew Feinsod M.D. | Chief Medical Officer |
| Kristine Curtiss | Senior Vice President of Clinical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Aug 13, 2025 | 8-K | Current Report |
| Aug 13, 2025 | 8-K | Current Report |
| Jul 29, 2025 | SCHEDULE 13G/A | Filing |
| Jul 1, 2025 | ARS | Filing |
| Jul 1, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 1, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 20, 2025 | 8-K | Current Report |
| Jun 4, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 15, 2025 | SCHEDULE 13G/A | Filing |